Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides cust… Read more
Gempharmatech Co. Ltd. A (688046) - Net Assets
Latest net assets as of June 2025: CN¥2.17 Billion CNY
Based on the latest financial reports, Gempharmatech Co. Ltd. A (688046) has net assets worth CN¥2.17 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.80 Billion) and total liabilities (CN¥630.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.17 Billion |
| % of Total Assets | 77.47% |
| Annual Growth Rate | 54.73% |
| 5-Year Change | 224.8% |
| 10-Year Change | N/A |
| Growth Volatility | 75.69 |
Gempharmatech Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Gempharmatech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gempharmatech Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Gempharmatech Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.13 Billion | +0.47% |
| 2023-12-31 | CN¥2.12 Billion | +7.43% |
| 2022-12-31 | CN¥1.98 Billion | +151.74% |
| 2021-12-31 | CN¥785.63 Million | +19.53% |
| 2020-12-31 | CN¥657.24 Million | +173.31% |
| 2019-12-31 | CN¥240.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gempharmatech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1704.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥435.31 Million | 20.39% |
| Other Components | CN¥1.70 Billion | 79.61% |
| Total Equity | CN¥2.13 Billion | 100.00% |
Gempharmatech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Gempharmatech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Revance Therapeutics, Inc.
NASDAQ:RVNC
|
$333.19 Million |
|
AXTRART_AXTRA FUTURE CITY
BK:AXTRART
|
$333.28 Million |
|
Blend Labs Inc
NYSE:BLND
|
$333.30 Million |
|
Trilogy Metals Inc
NYSE MKT:TMQ
|
$333.43 Million |
|
Alivus Life Sciences Limited
NSE:ALIVUS
|
$333.13 Million |
|
Amorepacific Group
KO:002795
|
$333.07 Million |
|
Betagro Public Company Limited
F:J74
|
$333.04 Million |
|
Alligo AB Series B
ST:ALLIGO-B
|
$332.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gempharmatech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,124,656,444 to 2,134,726,320, a change of 10,069,875 (0.5%).
- Net income of 109,819,819 contributed positively to equity growth.
- Dividend payments of 80,114,032 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥109.82 Million | +5.14% |
| Dividends Paid | CN¥80.11 Million | -3.75% |
| Other Changes | CN¥-19.64 Million | -0.92% |
| Total Change | CN¥- | 0.47% |
Book Value vs Market Value Analysis
This analysis compares Gempharmatech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 22.62x to 2.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥0.67 | CN¥15.11 | x |
| 2020-12-31 | CN¥1.83 | CN¥15.11 | x |
| 2021-12-31 | CN¥1.92 | CN¥15.11 | x |
| 2022-12-31 | CN¥4.82 | CN¥15.11 | x |
| 2023-12-31 | CN¥5.18 | CN¥15.11 | x |
| 2024-12-31 | CN¥5.21 | CN¥15.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gempharmatech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.14%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.99%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.21x
- Recent ROE (5.14%) is below the historical average (10.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 14.45% | 18.03% | 0.50x | 1.61x | CN¥10.70 Million |
| 2020 | 11.63% | 29.18% | 0.30x | 1.34x | CN¥10.71 Million |
| 2021 | 15.90% | 31.72% | 0.37x | 1.34x | CN¥46.36 Million |
| 2022 | 8.33% | 31.88% | 0.23x | 1.14x | CN¥-33.11 Million |
| 2023 | 7.48% | 25.54% | 0.24x | 1.21x | CN¥-53.55 Million |
| 2024 | 5.14% | 15.99% | 0.27x | 1.21x | CN¥-103.65 Million |
Industry Comparison
This section compares Gempharmatech Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gempharmatech Co. Ltd. A (688046) | CN¥2.17 Billion | 14.45% | 0.29x | $333.19 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |